Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer

Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer

Background Immune checkpoint inhibitors (ICIs), including anti-PD-1 therapy, have limited efficacy in patients with microsatellite stable (MSS) colorectal cancer (CRC). Interleukin 17A (IL-17A) activity leads to a protumor microenvironment, dependent on its ability to induce the production of inflam...

Full description

Bibliographic Details
Main Authors: Chao Liu, Yang Yao, Jiaqi Shi, Ruiqi Liu, Bojun Wang, Jie Lian, Haoxiu Sun, Chunhui Zhang, Lin Fang, Xin Guan, Shuling Han, Fei Zhan, Shengnan Luo, Yuanfei Yao, Tongsen Zheng, Yanqiao Zhang
Format: Article
Language:English
Published: BMJ Publishing Group 2021-01-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/1/e001895.full

Internet

https://jitc.bmj.com/content/9/1/e001895.full

Similar Items